214,288 Shares in Apyx Medical Corporation $APYX Purchased by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC bought a new stake in shares of Apyx Medical Corporation (NASDAQ:APYX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 214,288 shares of the company’s stock, valued at approximately $962,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in APYX. Citadel Advisors LLC acquired a new position in shares of Apyx Medical during the third quarter worth approximately $28,000. Nwam LLC acquired a new stake in shares of Apyx Medical in the first quarter worth $47,000. Osaic Holdings Inc. bought a new position in Apyx Medical during the second quarter worth $50,000. Franklin Resources Inc. bought a new position in Apyx Medical during the third quarter worth $59,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Apyx Medical during the 2nd quarter valued at $62,000. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical Price Performance

Shares of Apyx Medical stock opened at $3.08 on Monday. The firm has a market cap of $129.73 million, a P/E ratio of -15.40 and a beta of 1.39. The firm’s 50-day simple moving average is $3.87 and its 200-day simple moving average is $3.84. Apyx Medical Corporation has a twelve month low of $1.70 and a twelve month high of $5.08. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $13.88 million during the quarter, compared to analyst estimates of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. As a group, research analysts expect that Apyx Medical Corporation will post -0.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

APYX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. HC Wainwright assumed coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.